Iqvia Holdings Inc (NYSE:IQV) Sees Large Decline in Short Interest

Iqvia Holdings Inc (NYSE:IQV) was the recipient of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 2,474,900 shares, a decrease of 12.4% from the June 30th total of 2,824,800 shares. Based on an average daily trading volume, of 1,270,000 shares, the days-to-cover ratio is currently 1.9 days. Currently, 1.4% of the company’s shares are short sold.

IQV has been the subject of several recent analyst reports. Wells Fargo & Co increased their price target on Iqvia from $170.00 to $178.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Barclays set a $180.00 price target on Iqvia and gave the stock a “buy” rating in a report on Monday, July 15th. Stifel Nicolaus increased their price target on Iqvia from $167.00 to $178.00 and gave the stock a “buy” rating in a report on Wednesday, June 19th. TheStreet downgraded Iqvia from a “b” rating to a “c+” rating in a report on Wednesday, May 1st. Finally, Leerink Swann initiated coverage on Iqvia in a report on Tuesday, May 28th. They issued an “outperform” rating and a $136.38 price target for the company. Three investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $161.13.

In other Iqvia news, insider Kevin C. Knightly sold 6,945 shares of the stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $158.53, for a total value of $1,100,990.85. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Ari Bousbib sold 96,000 shares of the stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $160.00, for a total value of $15,360,000.00. The disclosure for this sale can be found here. Insiders sold 198,945 shares of company stock worth $30,860,991 in the last three months. Insiders own 6.00% of the company’s stock.



Several large investors have recently bought and sold shares of IQV. Vanguard Group Inc. grew its stake in Iqvia by 2.0% in the second quarter. Vanguard Group Inc. now owns 18,316,909 shares of the medical research company’s stock valued at $2,947,191,000 after purchasing an additional 352,839 shares in the last quarter. BlackRock Inc. grew its stake in Iqvia by 9.3% in the second quarter. BlackRock Inc. now owns 13,436,830 shares of the medical research company’s stock valued at $2,161,986,000 after purchasing an additional 1,146,138 shares in the last quarter. FMR LLC grew its stake in Iqvia by 27.5% in the first quarter. FMR LLC now owns 5,376,239 shares of the medical research company’s stock valued at $773,372,000 after purchasing an additional 1,158,248 shares in the last quarter. AQR Capital Management LLC grew its stake in Iqvia by 18.2% in the first quarter. AQR Capital Management LLC now owns 3,642,793 shares of the medical research company’s stock valued at $519,972,000 after purchasing an additional 561,276 shares in the last quarter. Finally, Janus Henderson Group PLC grew its stake in Iqvia by 19.3% in the second quarter. Janus Henderson Group PLC now owns 3,630,639 shares of the medical research company’s stock valued at $584,166,000 after purchasing an additional 588,179 shares in the last quarter. Institutional investors and hedge funds own 92.29% of the company’s stock.

Shares of NYSE:IQV traded down $5.92 during mid-day trading on Wednesday, reaching $151.16. 817,749 shares of the stock were exchanged, compared to its average volume of 1,267,256. The company has a current ratio of 1.14, a quick ratio of 1.14 and a debt-to-equity ratio of 1.72. The company has a market capitalization of $30.52 billion, a P/E ratio of 29.52, a P/E/G ratio of 1.90 and a beta of 0.88. Iqvia has a one year low of $104.90 and a one year high of $164.13. The business’s 50 day moving average price is $157.88.

Iqvia (NYSE:IQV) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $1.39 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.38 by $0.01. The business had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.70 billion. Iqvia had a return on equity of 15.95% and a net margin of 2.31%. Iqvia’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period last year, the company earned $1.29 earnings per share. As a group, research analysts forecast that Iqvia will post 5.86 EPS for the current fiscal year.

Iqvia Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Further Reading: Economic Bubble

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.